Nanobac Announces Baylor College of Medicine Initial Results for
Nanoparticle and Gall Stone Formation Study
Jan 15 2008, 9:23 AM EST

News source: Business Wire

Nanobac Pharmaceuticals Inc. (OTCBB:NNBP) ("Nanobac" or "the Company")
announces that scientists at the Baylor College of Medicine, working
under a collaborative agreement with Nanobac, have cited evidence
showing the presence of calcifying nanoparticles (CNPs) in surgically
resected gallbladders with cholelithiasis (Gall Stones). This
potentially represents a previously unrecognized factor in the
development of cholecystitis and cholelithiasis disease.

The project seeks to determine if human cell derived nanoparticles are
pathogenic and induce inflammatory (cholecystitis) and calcific
pathologic (cholelithiasis) disease. The project also seeks to confirm
prior Nanobac studies, conducted in China, that Nanobac's diagnostic
test specifically identifies CNPs.

The study results suggest a strong association between CNPs and
cholelithiasis and conclude that it is conceivable that a specific
therapy for CNPs may prevent cholecystitis and reduce the need for
surgical intervention. The results were given at the 58th Annual
Meeting of the American Association for the Study of Liver Diseases.
The abstract was published in "Hepatology 46(4) 699A 1036 Suppl S,
2007" issue.

Dr. Maniscalco, co-chair of Nanobac, stated, "We believe that CNPs
play a major role in pathologic calcification and a multitude of
associated disease states such as calcification of arteries and
organs. This study, conducted by one of the lead medical and research
facilities in the United States, lends credence to our beliefs."

Nanobac Pharmaceuticals Inc. is headquartered in Tampa, Florida. For
more information, visit our website at: http://www.nanobac.com.